{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-25-000058","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2025-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.045629+00:00","generated_at":"2026-05-17T02:18:52.963836+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amphastar enters exclusive BAQSIMI distribution deal for Greater China with related party","bullets":["Exclusive distributor Chengong will market BAQSIMI in Mainland China, Taiwan, Hong Kong, Macau.","Chengong must obtain regulatory approvals and conduct post-marketing clinical trials.","10-year term; minimum purchase amounts per contract year; profit sharing above floor price.","Related party: CEO Jack Zhang and Chairman Mary Luo family own majority of Chengong's parent Hanxin.","Audit Committee approved the deal; total revenue over 10 years not yet determinable."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-25-000058","json":"https://secwatch.observer/filing/0001297184-25-000058.json","markdown":"https://secwatch.observer/filing/0001297184-25-000058.md","text":"https://secwatch.observer/filing/0001297184-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/0001297184-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718425000058/amph-20251021x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:18:52.963836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}